In the U.S., we market UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, CIMERLI® (ranibizumab-eqrn), a biosimilar of Lucentis® and YUSIMRY™ (adalimumab-aqvh), a biosimilar of Humira®.
Our strategy is to invest cash flows from our commercial biosimilar business to build an immuno-oncology franchise that will be synergistic with our proven commercial capabilities in oncology.
In 2021, we in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. A biologics license application for toripalimab for the treatment of nasopharyngeal carcinoma is under review by the FDA.
Through our acquisition of Surface Oncology, Coherus’ immuno-oncology pipeline now includes casdozokitug (SRF388), a novel first-in-class anti-IL-27 antibody currently being evaluated in Phase 1/2 clinical trials in lung and liver cancer. CHS-114 (SRF114) is a highly selective, competitively positioned anti-CCR8 antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors.
Our earlier-stage immuno-oncology pipeline includes CHS-006, a TIGIT-targeted antibody, being evaluated in a Phase 1/2 trial in combination with toripalimab in patients with advanced solid tumors. Coherus is discovering and developing additional immuno-therapies for cancer targeting novel pathways such as ILT4 and others.
